Mantle Cell Lymphoma

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

Research Summary
physician with clipboard
Research Summary
Phase 2 MRD-Driven Acalabrutinib Triplets Show Molecular Complete Responses in Frontline MCL
05/14/2026
Anthony Calabro, MA
In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.
05/14/2026
Research Summary
doctor with clipboard talking to patient
Research Summary
Phase 1/2 BRUIN: Pirtobrutinib Maintains Patient-Reported Outcomes in CLL/SLL and MCL
05/14/2026
Anthony Calabro, MA
In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.
05/14/2026
FDA Approval
FDA sign
FDA Approval
FDA Grants Accelerated Approval to Sonrotoclax (Beqalzi) for Relapsed or Refractory MCL
05/14/2026
Ashton L. Stahl
The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.
05/14/2026